INCOGNITO-SOFTWARE
14.3.2022 14:02:05 CET | Business Wire | Press release
Incognito Software Systems Inc. , a leading global provider of broadband service orchestration software solutions for digital service providers, announces that Optima Italia S.p.A. has gone live with Incognito’s Digital Experience (DX) Solution to streamline and improve the customer experience. With Incognito, Optima can centralize and streamline the management of all devices in its network to deliver an uninterrupted, high-quality customer experience using a carrier-grade solution that can scale with their network and service growth.
As a leading Italian digital company service provider, Optima offers an integrated collection of services, including electricity, gas, mobile, and Internet for business and residential markets. To support a significant and growing customer base across major centers, Optima required a solution to scale operations by replacing time- and labor-intensive manual processes with an industry awarded platform. Underpinned by Incognito’s fully featured Broadband Forum-compliant Auto Configuration Server (ACS) , the Digital Experience smart platform automates the resolution of technical issues that impact service quality.
Optima selected Incognito to support them in their automation efforts based on Incognito’s expertise enhancing subscriber experience, reducing operational costs, and supporting the delivery of innovative services into the connected home. “It was quickly apparent that Incognito could offer a great platform implementation, with system go-live in a matter of weeks,” said Paolo Primiani, Network & Voice engineer at Optima Italia.
“We are very proud to be working with Optima Italia as a technology partner for their rollout of high-speed fiber broadband services to customers across its service areas,” said Ricardo Gonzalez, VP of Sales at Incognito. “Optima is one of the leading broadband providers in Italy, respected for their dedication to customer experience. Our mission is to provide telecom operators with tools that help them increase efficiency while reducing costs, and we look forward to contributing to Optima’s success.”
The Digital Experience Solution (DX) is an industry awarded platform, used around the world by premier broadband service providers to manage and orchestrate internet of things (IoT) and customer premise equipment (CPE) with Broadband Forum’s TR-069, User Services Platform (USP / TR-369) , and other management protocols. To learn more about Digital Experience Solution and Incognito’s suite of orchestration solutions, visit www.incognito.com .
About Incognito
Incognito Software Systems Inc. provides service orchestration software and services that help digital service providers manage the next-generation broadband experience. Over 200 customers worldwide, including Claro, Cox, Digicel, Globe, and Orange, leverage Incognito solutions to fast-track the introduction of innovative broadband services over fiber, cable, and fixed wireless technologies, while delivering a great customer experience. The company is a division of the Lumine Group , a portfolio of Constellation Software Inc. , the largest independent software company in Canada. Visit www.incognito.com or follow us on LinkedIn and Twitter .
About Optima Italia
Optima Italia S.p.A., is a leading Italian digital company for the integrated provision of energy (electricity and gas) and telecommunications (internet, telephone, and mobile) services for the business and consumer markets. Optima was founded in 1999 by entrepreneurs Danilo Caruso and Alessio Matrone with the objective of creating a service company to simplify life for families and businesses. Visit www.optimaitalia.com , or follow on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005117/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom